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Abstract: The chemical processes taking place in humans intersects the myriad of metabolic pathways
occurring in commensal microorganisms that colonize the body to generate a complex biochemical
network that regulates multiple aspects of human life. The role of tryptophan (Trp) metabolism at the
intersection between the host and microbes is increasingly being recognized, and multiple pathways
of Trp utilization in either direction have been identified with the production of a wide range of
bioactive products. It comes that a dysregulation of Trp metabolism in either the host or the microbes
may unbalance the production of metabolites with potential pathological consequences. The ability
to redirect the Trp flux to restore a homeostatic production of Trp metabolites may represent a valid
therapeutic strategy for a variety of pathological conditions, but identifying metabolic checkpoints
that could be exploited to manipulate the Trp metabolic network is still an unmet need. In this review,
we put forward the hypothesis that pyridoxal 5′-phosphate (PLP)-dependent enzymes, which regulate
multiple pathways of Trp metabolism in both the host and in microbes, might represent critical nodes
and that modulating the levels of vitamin B6, from which PLP is derived, might represent a metabolic
checkpoint to re-orienteer Trp flux for therapeutic purposes.
Keywords: tryptophan; microbiome; pyridoxal 5′-phosphate
1. Introduction
Tryptophan (Trp) is an aromatic amino acid characterized by the presence of a side chain indole,
a bicyclic structure consisting of a benzene ring fused to a pyrrole ring [1]. The indole group is
responsible for the peculiar structural and functional properties of Trp. Indeed, indole makes Trp
a non-polar amino acid, which is important for stabilizing the structure of proteins, and is the
scaffold of a series of Trp-derived metabolites with wide-ranging physiological activities [1] (Figure 1).
Trp metabolites can be generated not only by the host, but also by other organisms that interact with
the host. For instance, the microbiota, i.e., the commensal microbes that inhabit the surfaces exposed
to the external environment, such as the skin and the respiratory, gastrointestinal, and genitourinary
tracts, can generate bioactive Trp metabolites [2]. Two characteristics make Trp an intriguing molecule
in the relationship between the host and other organisms. First, Trp is an essential amino acid in
mammals and needs to be acquired from the diet, whereas, in general, bacteria, fungi, and higher
plants express enzymes for Trp biosynthesis. Second, the Trp metabolic pathways and the resulting
bioactive molecules can either be shared or differ between mammals and other organisms [3]. All these
characteristics create a network of inter-dependency and connectivity, centered around Trp and
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molded by a plethora of Trp-derived metabolites, which is critical for both the regulation of host
physiology and the modulation of the interaction between the host and other organisms. Indeed,
a dysregulation of Trp metabolism has been associated with the occurrence of diverse pathological
conditions and the therapeutic efficacy of balancing among the distinct fates of Trp metabolism
is increasingly being recognized [4]. This therapeutic effort would benefit from a comprehensive
assessment of the complexity of Trp metabolism in the host and microbes. For instance, what orientates
the flux of Trp along the different metabolic pathways in physiological conditions? Is there a common
denominator among all, or at least some, of the metabolic pathways? Is it possible to identify a
checkpoint that coordinates the traffic of Trp? A biochemical investigation of Trp metabolism may
provide an interpretative key to dissect this complexity.
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Vitamin B6 includes a group of chemically similar compounds, or vitamers, that are derivatives
of 2-methyl-3-hydroxy-5-hydroxymethyl-pyridine [5]. In the form of pyridoxal 5′-phosphate (PLP)
(Figure 2A), vitamin B6 works as a co-factor for more than 140 enzymatic reactions, corresponding to
≈4% of all classified activitie [6]. Interestingly, critical steps in the synthesis and metabolism of Trp in
mammals and microbes are regulat d by PLP-dependent enzym s. It is therefore likely that vitamin
B6, fro which the a tive form PLP is derived, might intersect the Trp metabolism to regulate its flux
along the different metaboli pathways, thus working as a metabolic c eck oint.
In this review, w provide an overview of the metabolic dependence between vitamin B6 and
Trp in mammals and microbes, then discuss how the regulation of Trp flux may occur in function of
vitamin B6 levels, and finally propose how the modulation of vitamin B6 levels may have potential
therapeutic implications in pathological conditions.
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2. PLP-Dependent Enzymes in the Flux of Trp in Mammals and Microbes
As previously stated, Trp is essential in mammals while, in general, bacteria, fungi, and higher
plants can synthesize Trp via the shikimate pathway, a seven-step metabolic route that collectively
converts phosphoenol pyruvate and erythrose-4-phosphate into chorismate, a substrate for the
three aromatic amino acids Trp, phenylalanine (Phe), and tyrosine (Tyr) [7].‘In the Trp biosynthetic
pathway, the subsequent action of four enzymes converts chorismate into indole-3-glycerol phosphate,
which becomes the substrate of tryptophan synthase [8]. Tryptophan synthase is an α2β2 tetrameric
PLP-dependent enzyme that catalyzes Trp synthesis, thus making the final step of the biosynthetic
pathway dependent on vitamin B6 (Figure 1).
Once produced or acquired from the diet, Trp can then be metabolized along different metabolic
pathways (Figure 1). Humans mostly rely on Trp acquired from the diet as there is no evidence that Trp
produced by bacteria could work as a Trp source [4]. Upon absorption by the gut, Trp is then transported
to the liver via the hepatic portal system where the majority (around 90%) is metabolized in the
kynurenine (Kyn) pathway that leads to the production of nicotinamide adenine dinucleotide (NAD+).
Trp can also be metabolized in other cell types, such as endothelial cells, fibroblasts and immune cells [9].
The rate-limiting step in the Kyn pathway is represented by the enzymes indoleamine-2,3-dioxygenase
1 (IDO1), IDO2, and tryptophan-2,3-dioxygenase (TDO), which catabolize Trp to N’-formylkynurenine,
which is then hydrolyzed to Kyn. Interestingly, although the dioxygenases IDOs and TDO do not use
PLP as a cofactor, they can be considered indirectly dependent on PLP as they contain a heme group
whose rate of synthesis is determined by the activity of the PLP-dependent enzyme 5-aminolevulinate
synthase [10]. In particular, IDO1 is present in cells in the apo-form and can be activated upon addition
of exogenous heme [11]. The role of heme binding for regulating IDO1 activity is also demonstrated
by the finding that synthetic compounds targeting apoIDO1 are effective as inhibitors at both the
protein and cellular levels [12]. In the path to the production of nicotinamide, Kyn is then converted to
3-hydroxykynurenine (3-hydroxykyn) by the activity of kynurenine hydroxylase (Kyn monooxygenase).
Kyn and 3-hydroxykyn represent crucial branching points for the generation of Trp metabolites that
depend on vitamin B6. Indeed, they can be substrates for the activity of two PLP-dependent enzymes,
kynurenine aminotransferase (KAT) and kynureninase (KYNU). KAT converts Kyn and 3-hydroxykyn
to kynureninate and xanthurenate, respectively, while anthranilate and 3-hydroxyanthranilate are
generated by the activity of KYNU. 3-Hydroxyanthranilate can then be converted along the path to
nicotinamide production while the other etabolites have distinct fates. The dependency of KYNU
and KAT from PLP have led to the use of Trp metabolites of the Kyn pathway as potential markers of
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functional vitamin B6 status [13]. In particular, since KYNU is more susceptible to vitamin B6 deficiency
than KAT, Trp metabolism is shifted towards increased production of xanthurenate [14]. In parallel,
the levels of Kyn and 3-hydroxykyn are higher [15], likely dependent on increased flux of Trp along
the Kyn pathway. By taking into account different parameters, including enzyme characteristics and
metabolite abundances, the changes that occur upon B6 deficiency can be predicted by mathematical
modelling [16]. Thus, analysis of Trp metabolites can provide accurate prediction of functional B6
status in health and disease [17,18].
Limited amounts of Trp may be used in other pathways such as for the production of the
neuroactive molecule serotonin [2] (Figure 1). Interestingly, PLP-dependent activities also regulate
the metabolic pathway that converts Trp to serotonin. Indeed, a Trp hydroxylase (Tph1, Tph2) first
converts Trp to 5-hydroxytryptophan, which in turn is metabolized to serotonin by the PLP-dependent
enzyme aromatic-L-amino acid decarboxylase (AADC). The metabolic dependence of serotonin from
vitamin B6 has been evaluated in studies on the symptoms of depression. Indeed, it was first found that
the levels of vitamin B6 were associated with depression [19], and it was then shown that vitamin B6
supplementation can protect from depression in certain clinical settings. All in all, these results indicate
that the metabolism of Trp in mammals is dependent on vitamin B6 as two of the main Trp-metabolic
pathways are regulated by PLP-dependent enzymes, thus making vitamin B6 a plausible metabolic
checkpoint in the regulation of Trp flux.
A similar situation is also present in the microbial Trp metabolism (Figure 1). Dissection of the
Trp metabolism in the gut microbiome has demonstrated the production of a wide variety of Trp
metabolites [20]. The main pathways of Trp degradation include as a first step the production of indole,
indole-3-pyruvic acid, tryptamine, and indole-acetamide [20]. The first three products are generated
by the activity of PLP-dependent enzymes: indole is produced by tryptophanase, a PLP-enzyme
that is activated by potassium ions; indole-3-pyruvic acid by PLP-dependent aromatic amino acid
aminotransferases (AroAT); and tryptamine by a Trp decarboxylase, again dependent on PLP.
Collectively, these data indicate that vitamin B6 in the active form of PLP may represent a
common denominator among the major pathways of Trp metabolism in both the host and microbes,
thus suggesting that its levels may regulate the flux of Trp utilization and the generation of selective
Trp metabolites.
3. A Biochemical Overview of Microbial and Host Trp-Metabolizing Enzymes
The main metabolic role of PLP-dependent enzymes is the synthesis, interconversion,
and catabolism of amino acids, as well as the synthesis of secondary metabolites derived from
amino acids, such as in particular neurotransmitters and hormones [21]. Notwithstanding their
high versatility, PLP enzymes share some common features at both a functional and structural
level [22,23]. The carbonyl group of the coenzyme forms a Schiff base linkage with the ε-amino
group of an active site lysine residue, generating a complex called internal aldimine. Upon substrate
binding, the internal aldimine is converted to the external aldimine, in which PLP is bound to the
α-amino group of the amino acid substrate. The external aldimine intermediate is common to all
PLP-catalyzed reactions, and it represents a crucial step to determine reaction specificity [24]. From the
external aldimine, the reaction proceeds differently on the basis of which bond is broken at the
Cα of the substrate, giving rise to transamination, racemization, decarboxylation, β-replacement,
or β-elimination reactions [23,25] (Figure 2B). In each case, the positive charge of the pyridine nitrogen
acts as an electron sink and stabilizes negatively charged reaction intermediates. According to the
Dunathan hypothesis, the main determinants in controlling which one of the three labile bonds at Cα
should be broken are stereoelectronic effects. They arise from the specific conformation of the external
aldimine, so that the bond to be broken is that positioned perpendicular to the pyridine ring of the
coenzyme. This happens because the resulting carbanion is better stabilized by resonance with the
conjugated Π system due to the electronic delocalization of the negative charge [26]. The reaction and
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substrate specificity is dictated by the apoprotein, which drives the catalytic power of PLP toward the
stabilization of different intermediates and favors the interaction with different ligands [24].
Due to their involvement in both microbial and host metabolism, PLP enzymes have become
targets of clinical interest for different disorders including infectious diseases, neurologic diseases,
cancer, and rare metabolic disorders [5,27–30]. This is especially true for members of the family
involved in the different pathways of Trp metabolism, whose characteristics are described in the
following sections.
3.1. Tryptophan Synthase (TS)
TS (E.C. 4.1.2.20) catalyzes the last two steps of Trp synthesis in bacteria, yeast, molds, and plants [8]
(Figure 3A). TS from E. coli and S. typhimurium are the most characterized enzymes and are often
used as models for other homologous proteins [8,31,32]. The bacterial enzyme is an α2β2 tetrameric
complex. Subunits α and β are encoded by the two adjacent genes of the trp operon, trpA and trpB [33],
and catalyze two different reactions in a multi-step process. Subunit α converts indole-3-glycerol
phosphate into glyceraldehyde 3-phosphate and indole by a reversible retro-aldol cleavage occurring
through acid–base catalysis. The latter product, along with L-serine, is the substrate of subunit β,
which utilizes PLP as a cofactor and catalyzes the β-replacement of the hydroxyl group of L-serine
with the indole moiety, generating Trp [34]. At the β active site, the external aldimine with L-serine is
first formed. Then, abstraction of the substrate α proton occurs, generating a quinonoid intermediate
from which the hydroxyl group is eliminated giving the aminoacrylate species. The latter then reacts
with indole leading to the Trp external aldimine passing through a second quinonoid intermediate [35].
α and β subunits are arranged in a αββα linear complex, with the α subunit displaying a TIM barrel
conformation and the β subunit showing the typical arrangement of fold type II PLP enzymes [36].
An intriguing property of TS is substrate channeling. Indole, representing the product of the first
reaction step and the substrate of the second one, is transferred from the α to the β subunit via
an interconnecting tunnel. This explains why the two activities are structurally and functionally
interconnected, and the formation of the αββα complex influences both catalytic efficiency and subunit
switch from an open inactive to a closed active conformation [34]. The activity of TS β subunit is also
allosterically regulated by monovalent cations, which increase catalytic efficiency by at least one order
of magnitude, as well as by α subunit ligands [37,38].
The fact that Trp availability is essential for microbial survival and that the enzymes involved
are absent in humans makes TS an attractive drug target for antibiotics development, although it
should be underlined that Trp is essential only when dietary supply is low, thus explaining why some
bacterial species maintain the trp operon at a very low level of functionality [33]. The regulation of the
trp operon is under the control of two main signals, namely, the intracellular Trp concentration and the
presence of charged/uncharged tRNATrp [33]. In Gram-negative bacteria, transcription is regulated
by various mechanisms, including repression through a Trp-activated TrpR repressor, attenuation by
sensing the presence of uncharged tRNATrp, and response to the accumulation of Trp biosynthesis
intermediates such as indole-glycerolphosphate. Similar signals are also sensed in Gram-positive
bacteria but with different strategies. In B. subtilis, a Trp-activated trp RNA-binding attenuation
protein (TRAP) is produced, whose activity is dependent on both Trp and tRNATrp levels, the latter
through the production of an anti-TRAP protein [39]. In other Gram-positive bacteria, no TRAP protein
is produced, but uncharged tRNATrp are sensed through a T-box mechanism [40]. TS expression is
required for the survival of M. tuberculosis to counteract the adaptive immune response, and of other
Gram-positive and Gram-negative bacteria [38]. In this regard, some active site ligands behaving
as allosteric inhibitors of the M. tuberculosis enzyme have been identified through high-throughput
screening and crystallographic studies [41,42]. The key role of Trp synthesis in M. tuberculosis is also
demonstrated by the ability of microbiota-derived indole-propionic acid to inhibit bacterial growth in
both in vitro and in vivo models [43,44]. As a Trp analog, indole-propionic acid binds an allosteric site
of anthranilate synthase (TrpE), thus switching off Trp de novo synthesis by a regulatory feedback
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mechanism [45]. This action seems to be selective against mycobacteria, but the molecular reasons
underlying this selectivity are currently unknown.
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Notably, the resolution of the structure of TS β from E. coli in the holo- and apo-form
has confirmed that the coenzyme also plays a structural role. Indeed, PLP binds very tightly
(Kd ≈10 −7 M), and strengthens the interaction between the twoβ subunits in the dimer, increasing their
resistance to thermal stress. Moreover, it induces the transition from the open to the active closed
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form [46]. Thus, although Trp synthesis is known to be regulated by Trp itself by feedback inhibition
mechanisms [33], the possibility exists that it could be also influenced by vitamin B6 availability.
3.2. Tryptophan Indole Lyase (Trpase)
The bacterial enzyme responsible for indole production is Trpase (E.C. 4.1.99.1). Trpase is a
PLP enzyme that catalyzes a reversible β-elimination reaction converting L-Trp to indole, pyruvate,
and ammonium ion (Figure 3B). In E. coli, the enzyme is encoded by the tnaA gene of the tna operon,
which also comprises a Trp-specific membrane transporter for Trp uptake from the extracellular medium
encoded by the tnaB gene [47]. The detailed kinetic characterization of the Trpase reaction has indicated
that it consists of an electrophilic aromatic substitution occurring through a SE2 mechanism. Upon Trp
binding and external aldimine formation, the Cα-proton of the substrate is abstracted, generating a
quinonoid intermediate. The concerted reprotonation at Cβ/deprotonation of the aromatic ring leads
to the formation of indole and of an aminoacrylate intermediate. The subsequent transaldimination
regenerates the PLP form of the enzyme and iminopyruvate, which is hydrolyzed to pyruvate
and ammonium ion outside of the active site [48]. In vitro Trpase shows a wide substrate specificity,
being able to catalyze elimination reactions with different amino acid substrates. In addition, amino acid
compounds that cannot undergo elimination behave as competitive inhibitors of the enzyme [49].
The crystal structure of Trpase from Proteus vulgaris solved in 1998 [50] has revealed that it displays a
tetrameric assembly and belongs to the Fold Type I family, the most numerous group of PLP enzymes.
Each subunit is formed by a N-terminal stretch, a large domain comprising most of the active site,
and a small C-terminal domain. As in all members of the same family, each active site is located in a
pocket between the large and small domain made up of residues belonging to two different subunits
of a dimeric unit [51]. Monovalent cations influence Trpase tetramer stability and PLP binding, by
possibly forcing each subunit in a proper conformation for catalysis [52].
Data obtained in E. coli have clearly demonstrated that the concerted action of Trpase and the
TnaB transporter produce millimolar amounts of indole from exogenous Trp. This production mainly
occurs when high amounts of Trp are available, such as in the intestinal tract, where specific niches for
E. coli can form and give rise to high local intestinal indole concentrations [53]. More recently, it has
been reported that the trp operon displays a bistable behavior, and that the activity of Trpase can be
influenced by both glucose and Trp extracellular levels through a common signaling pathway [47].
No studies have been performed until now to define if the activity is also dependent on the levels
of coenzyme. It is generally assumed that the levels of vitamin B6 can influence the intracellular
levels of active PLP enzymes in different ways, including the change in the proportion of apoenzymes,
which are often more prone to degradation than the corresponding holoenzymes [54]. Considering that
Trpase is endowed with a relatively low affinity for PLP, the intracellular PLP concentration is in the
micromolar range [55], and apoTrpase undergoes cold inactivation [48], the possibility that Trpase
levels and activity could be influenced by vitamin B6 merits investigation.
3.3. Aromatic Amino Acid Aminotransferase (AroAT)
Enzymes named AroAT (E.C. 2.6.1.57) catalyze a reversible reaction converting Phe, Tyr, and/or
Trp to the corresponding α-keto acids (Figure 3C). The overall transamination occurs through a
ping-pong mechanism and can be described as two half-reactions. In the first half-reaction, the amino
donor binds to the enzyme in the PLP form, generating the external aldimine. Then, a proton shift
from Cα of the substrate moiety to the C4′ of the cofactor occurs, producing a ketimine intermediate,
generating the α-keto acid product and the enzyme with bound pyridoxamine phosphate (PMP).
In the second half-reaction, the amino acceptor substrate binds to the PMP-bound enzyme, generating a
second ketimine from which an inverse proton transfer from C4′ to Cα occurs, producing the external
aldimine of PLP with the α-amino acid product that is finally released [30,56].
AroATs are expressed by different organisms, including bacteria, plants, and fungi
(BRENDA database, www.brenda-enzymes.org/). An important feature of these enzymes is their
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broad substrate specificity, being able to use also dicarboxylic amino and oxo-acids as substrates [57],
which is paired by their functional heterogeneity in terms of metabolic role. AroAT from plants are
highly specific for Trp transamination, as a step for the synthesis of the plant hormone indoleacetic
acid [58]. In bacteria, they are mostly involved in the synthesis of Phe and Tyr from the corresponding
oxoacids [59,60]. AroAT from E. coli displays a Km for Trp one order of magnitude higher than that
for Tyr and Phe [61]. In Pseudomonas, different genes encoding AroATs are present with overlapping
metabolic activity, as shown by the fact that the mutation of one of them does not lead to auxotrophy
for Phe or Tyr [62]. Interestingly, an AroAT from Kleibsiella aerogenes is involved in the use of Trp as a
carbon source. No homologous enzyme is expressed by E. coli [59]. In the common gut bacterium
Clostridium sporogenes, Trp transamination by AroAT is the first step for the production of various
metabolically active compounds including indole pyruvic acid, which accumulates in the host serum
and probably mediates the microbe–host interactions regulating immune, metabolic, and neuronal
responses [43,63]. In fungi, the Aro8 gene encodes a versatile PLP-dependent AroAT whose metabolic
role is shared between the lysine synthesis by the aminoadipate pathway and the catabolism of aromatic
amino acids [64,65]. In C. albicans, Aro8 is a very versatile enzyme active against L-histidine, L-lysine,
and aromatic amino acids [64]. Aro8 from S. cerevisiae has been characterized both functionally and
structurally and has been found to be a homodimer belonging to fold type I that is able to use aromatic
amino acids as well as α-aminoadipate as substrates [66,67]. Interestingly, it shows a broad substrate
specificity and its role in KA production has been demonstrated [68]. An enzyme able to transaminate
Trp has also been identified in crude rat liver extracts, although it has been found that most of the
activity can be ascribed to the action of other enzymes, mainly tyrosine aminotransferase [69].
In general, AroAT have greater affinity for Phe and Tyr when compared to Trp; thus, their role
in Trp metabolism is probably largely dependent on Trp availability. Moreover, they bind PLP in a
very tight manner, as usually observed for aminotransferases [23], thus suggesting that their activity
would not be modulated by vitamin B6 levels. Nevertheless, since Trp transamination represents a key
step for the production of microbial metabolites that regulate host physiology, deciphering how it is
modulated by vitamin B6 levels could reveal unknown mechanisms related to the pathogenesis of
human diseases and possibly open therapeutic avenues.
3.4. Aromatic Amino Acid Decarboxylase (AADC)
The presence of PLP-dependent enzymes able to catalyze the decarboxylation of either Trp or
Trp-derived metabolites, namely AADC, has been described in both host and microbes. PLP-dependent
decarboxylation occurs when, upon substrate binding, the carboxyl group is released as CO2 producing
a quinonoid intermediate. The latter is then reprotonated at Cα, generating the amine product [70]
(Figure 3D). Most of the biochemical features known on AADC until now are related to the enzyme from
pig kidney, which shares 90% of sequence identity with the human counterpart. Spectroscopic, kinetic,
and mutagenesis studies have dissected the catalytic mechanism, discovered how reaction specificity
is dictated by the presence or absence of oxygen, and identified specific active site inhibitors [71–75].
Structurally, both microbial and mammalian AADC are homodimers and belong to the fold type I
family. Each subunit is formed by a large domain made up of aβ/α -barrel that contains the PLP binding
site and a C-terminal small domain. The monomer–monomer interface is very large because of the
presence of an N-terminal domain generating two α-helices that pack over the opposite subunit [73,76].
AADC displays high affinity for PLP [77], which also plays an important structural role for the protein.
In fact, the apo-form of human AADC shows an open conformation resulting from a 20 Å movement
of each subunit leading to the exposure of the active site to the solvent [78]. One of the most important
consequences of this structural change is the increased sensitivity of the apoenzyme to degradation, as
observed in rat brain cells [79]. This has led to the hypothesis that PLP availability could influence the
amount of functional enzyme present in the brain [78].
Although microbial and host AADC seem to share most of their biochemical features, their substrate
preferences and physiological role seem different. Human AADC is the enzyme responsible for
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dopamine and serotonin biosynthesis, starting from the corresponding amino acids L-dopa and
5-hydroxyTrp, respectively [70]. AADC is expressed in both neuronal and non-neuronal tissues,
with the latter being found mainly in the kidneys and in the gastrointestinal tract [80]. In the gut,
enteroendocrine cells called enterochromaffin cells play a sensor role for stimuli coming from the
lumen and are mainly responsible for serotonin production. Serotonin produced in the gut mediates a
variety of processes including peristalsis, secretion, vasodilation, and perception of pain or nausea [80].
An altered production of serotonin in the gut is also observed in several pathologic conditions related to
inflammation, such as inflammatory bowel disease, colitis, and celiac disease. It has been demonstrated
in various experimental settings that the rate-limiting step of serotonin synthesis is Trp hydroxylation
in cerebral tissues. The latter activity is mainly influenced by Trp availability, because of the low Km of
the hydroxylase for the substrate [81]. However, it has been shown that neuronal AADC activity is
reduced in the case of vitamin B6 deficiency, either as a consequence of inherited conditions or as a
side-effect of pharmacological treatments [82]. Thus, the decarboxylation step can become limiting
under conditions of PLP deficiency in the CNS [83,84]. Whether a similar regulation also occurs at
intestinal level remains to be defined.
The presence of a microbial enzyme showing AADC activity has been also found in 2014 by
Williams and co-authors [76], who described a PLP enzyme produced by the two human commensals
Clostridium sporogenes and Ruminococcus gnavus, showing Trp decarboxylating activity that generates
tryptamine. These enzymes show a preference for Trp over Phe and Tyr, and excrete tryptamine in
the extracellular medium. Interestingly, in silico data suggest that homologues of these enzymes
could be present in about 10% of the human microbiome [76]. The production of tryptamine by
the gut microbiome represents a very important route of Trp metabolism that could influence host
metabolism. Indeed, tryptamine levels upon colonization of germ-free mice with human stool increases
by about 200-fold. Recently, it has been demonstrated that bacterially produced tryptamine accelerates
gastrointestinal transit through stimulation of GPCR receptors located in the intestinal epithelium [85].
In cerebrospinal fluid, tryptamine produced by AADC is the precursor of IAA, one of the Trp catabolites
involved in the regulation of the gut–brain axis [86,87]. Thus, host physiology is influenced by a
bacterial product of Trp metabolism, therein further supporting the pivotal role of PLP enzymes as
therapeutic targets at the host–microbe interface.
3.5. Kynurenine Aminotransferase (KAT) and Kynureninase (KYNU)
The Kyn pathway (KP) is one of the major players in determining the plasmatic levels of
circulating Trp and of Trp metabolites, being responsible for the fate of about 95% of Trp. The KP
is present in both the liver and peripheral tissues, serving different roles including the synthesis of
NAD+ and other intermediate bioactive compounds with important immunomodulatory functions [9].
Two PLP-dependent enzymes are involved in the KP, namely, KAT and KYNU.
KAT (E.C. 2.6.1.7) catalyzes the irreversible conversion of Kyn to kynurenic acid (KA) (Figure 3E),
an important neuroactive compound known to behave as an endogenous antagonist that binds the
glycine site in NMDA receptors [88], as well as agonist of receptors involved in immunomodulation
such as aryl hydrocarbon receptor (AhR) [89]. The enzyme also converts 3-hydroxykyn to xanthurenic
acid (XA) (Figure 3E), thus controlling the metabolic flux of the KP. The reaction consists of a classical
PLP-dependent transamination occurring through a ping-pong mechanism converting the amino acid
substrate, Kyn, into the corresponding α-ketoacid that spontaneously cyclizes to form KA and the
enzyme in the PMP form. The latter can then transfer the aminic group to an α-ketoacid, forming the
corresponding amino acid and regenerating PLP-KAT to complete the reaction cycle [23]. Four different
genes encoding KAT have been characterized in humans and rodents, which are named KAT I, II, III,
and IV [90]. The four isoenzymes are phylogenetically linked, and share many biochemical features,
but also show specific properties in terms of expression and catalytic efficiency toward Kyn and
3-hydroxykyn [90]. KAT I and KAT III share the highest sequence identity. Both are multi-functional
enzymes active toward a variety of α-amino acids (preferentially those with large neutral, aromatic,
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or sulfur-containing side chains) and α-ketoacids [91,92]. KAT II is known for its unique ability to
use α-aminoadipate as an amino donor, and it also uses α-ketoglutarate as an amino acceptor [93].
It is not active against 3-hydroxykyn. In bacteria and fungi, the enzyme is also involved in the lysine
metabolism [94,95]. KAT II is the most abundant isoenzyme in the human brain and is considered to
be mainly responsible for KA synthesis [96]. KAT III is also known as glutamine transaminase and has
only recently been included among KAT isoenzymes [97]. It shows cysteine conjugate β-lyase activity
and is abundantly expressed in the kidney and liver [98]. KAT IV is the most conserved isoenzyme,
active toward a plethora of amino and keto acids [99]. It displays aspartate aminotransferase activity,
and therefore is important for the transfer of NADH, reducing power from cytosol to mitochondria.
Moreover, it plays a key role for glutamate synthesis in the brain and is important for astrocytes
metabolism [100].
The crystal structures of the four KAT isoenzymes are available from different sources,
including that of human KAT I and KAT II, as well as of mouse KAT III and KAT IV [101]. All KATs
belong to the fold type I family, and are functionally obligated homodimers, being the active site
comprised between the two subunits. Although the solved structures are very similar, some key
peculiar features of each isoenzyme can be evidenced that mainly relate to the N-terminus of each
monomer, which shapes the ligand binding pocket. In KAT I, the N-terminus closes the entrance of the
active site upon ligand binding, mainly through the precise movement of Trp18, generating a relatively
rigid pocket that accommodates the aromatic substrate [102]. KAT III shows very similar features and
mainly differs for the residues located at the entrance of the active site, which in turn can determine
the different substrate specificities of the two proteins [92]. The structure of KAT IV is very similar to
that of mitochondrial aspartate aminotransferase and reveals a conformational change occurring upon
substrate binding involving the small domain that has the role of shielding the active site from the
solvent [99]. From a structural point of view, KAT II merits a special mention, because of a domain
swapping of the N-terminus of one subunit to the opposite one, which is different depending on the
chemical features of the ligand and explains the wide substrate specificity of this isoenzyme [103]. It is
worth noting that the differential structural features of the KATs have prompted the identification of
inhibitors specific for a particular isoenzyme as putative therapeutic approaches for CNS diseases [104].
KYNU (E.C. 3.7.1.3) catalyzes the hydrolytic cleavage of L-Kyn or 3-hydroxykyn to anthranilic
acid or 3-hydroxyanthranilic acid, respectively, as well as L-alanine [105] (Figure 3F). The enzyme is
expressed in both prokaryotes and eukaryotes. In bacteria, Kyn is the preferred substrate, and the
reaction probably plays an anabolic role for species that utilize Trp as a metabolic fuel. On the other
hand, eukaryotic KYNU is mainly active on 3-hydroxykyn and the Trp degradation pathway in
the liver allows the synthesis of NAD+ under conditions in which there is the need of niacin or
the production of quinolinic acid in immune cells [106,107]. The kinetic and structural features of
KYNU from different sources, including humans and Pseudomonas fluorescens, have been widely
investigated [106,107]. KYNU is a dimeric fold type I protein and shares many structural features
with aminotransferases, including key active site residues. The comparison between prokaryotic
and eukaryotic enzymes has also allowed for the identification of residues that govern substrate
preferences [108,109]. KYNU reaction occurs through a mechanism based on acid/base catalysis.
The bound substrate is first deprotonated at Cα and then reprotonated at C4′, generating a ketimine
intermediate. The addition of water to the ketimine, a step in which the phosphate of PLP plays an
important role, generates a gem-diol. The latter intermediate then undergoes Cβ–Cγ bond cleavage to
give the carboxylic acid product and an enamine intermediate. The subsequent protonation of the
enamine produces a pyruvate ketimine, which after deprotonation at C4′ and reprotonation at Cα
finally regenerates the enzyme in the PLP form and the second product alanine [106,107].
The pivotal role of PLP enzymes in the kynurenine pathway explains why it is sensitive to
alterations of the vitamin B6 status, as previously described.
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4. Vitamin B6 and the Regulation of Trp Flux in the Host and Microbes
In humans, vitamin B6 is acquired from the diet in the form of pyridoxine (PN) and its
phosphate (PNP) and glucoside (PNG) derivatives, PLP and pyridoxamine 5′-phosphate (PMP) [5]
(Figures 1 and 4).Int. J. Mol. Sci. 2020, 21, x FOR PEER REVIEW 11 of 21 
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IP: intestinal phosphatase; PK: pyridoxal kinase; PL: pyridoxal; PLP: pyridoxal 5′-phosphate; PM:
pyridoxamine; PMP: pyridoxamine 5′-phosphate; PN: pyridoxine; PNG: pyridoxine glucoside; PNP:
pyridoxine phosphate; PNPO: pyridox(am)ine phosphate oxidase.
The phosphorylated forms PNP, PLP, and PMP are dephosphorylated by intestinal phosphatases
while PNG is hydrolyzed by an intestinal glycosidase before absorption by intestinal cells. The resulting
PN, pyridoxal (PL), and pyridoxamine (PM) vitamers are then converted in the intestine or in the liver
(primary site) to the phosphorylated forms by the activity of pyridoxal kinase that generates PNP,
PLP, and PMP. Finally, pyridox(am)ine phosphate oxidase (PNPO) converts PNP and PMP to PLP,
which is then exported to the other tissues upon binding to lysine 190 of albumin [5]. When tissue
distribution was evaluated in mice fed different concentrations of PN, a great difference was found
among several tissues in their levels of B6 vitamers [110]. Interestingly, a dose-dependent accumulation
of PN and PLP was observed only in the small intestine and colon, but not in other organs [110],
indicating that intestinal cells can absorb and partially produce PLP in direct response to dietary intake
(Figures 1 and 4). In addition to the diet, vitamin B6 can also be produced by the microbiome in the
form of PLP [111] (Figures 1 and 4). In particular, two biosynthetic pathways have been described,
the DPX-dependent and DPX-independent pathways leading to PNP and PLP, respectively [112],
which associate with different phyla in the gut microbiome [111]. The microbial contribution to human
B6 requirements is consistent, such that dietary B6 deficiencies are rare [5]. Interestingly, the dietary
consumption of vitamins can influence the composition and structure of the colon microbiome [113].
In particular, a higher dietary consumption of vitamin B6, among others, was associated with a
greater richness and evenness of the gut microbiota [113]. Therefore, the gut represents the site for the
Int. J. Mol. Sci. 2020, 21, 5823 12 of 21
integration of dietary and microbial vitamin B6 sources that results in the adjustment of the B6 content
of intestinal cells and the composition of its associated microbiome.
As a corollary, the Trp metabolism by PLP-dependent enzymes in the gut may reflect the vitamin
B6 levels, and the production of Trp metabolites may vary accordingly. Indeed, a variation in the
availability of PLP is expected to modulate the production of Trp by the TS. We have previously shown
that the levels of Trp condition the host–fungal crosstalk via the microbiome [114]. In conditions of
unrestricted Trp availability, such as in IDO1-deficiency, Lactobacilli expand and produce an indole
derivative, indole-3-aldehyde (3-IAld), which activates the aryl hydrocarbon receptor (AhR) to produce
IL-22 and protect the intestinal barrier. On the contrary, in IDO1 sufficiency, the IDO1 pathway in
epithelial and dendritic cells prevail with the production of Kyn, the generation of Treg, and the
production of IL-10 [114]. Altered vitamin B6 levels may mimic this scenario. Indeed, the levels of PLP
not only influence the synthesis of Trp, but also the activity of AroAT and the generation of its substrate
indole-3-pyruvate, a potential precursor of 3-IAld, while the activity of IDO1 is not dependent on
PLP and the synthesis of Kyn may occur unperturbed. Therefore, vitamin B6 appears as a metabolic
checkpoint that orientates the flux of Trp in the host and the microbes to influence the immune response
to external challenges. The same role of vitamin B6 in the regulation of host–fungal interaction mediated
by the microbiota may apply to other tissues as well. Indeed, we have recently performed a multicenter,
prospective, observational study termed SNIF (Survey of Nasal InFection) in which hematological
patients were enrolled and their nasal and pharyngeal microbiomes were characterized, on average,
monthly from the enrollment and up to 6 months (manuscript submitted). Upon stratification of
samples according to their risk of developing invasive fungal infections on the basis of an algorithm
developed by the SEIFEM (Epidemiology Survey of Invasive Fungal Infections in Hematological
Malignancies) [115], the composition and the metabolic profile of the pharyngeal microbiome was
compared between low-risk and high-risk groups. Among others, the PLP biosynthesis and salvage
pathway was associated with the low-risk group and, in parallel, the levels of Trp and 3-IAld were
significantly higher in the low-risk than the high-risk group while Kyn levels were similar. Thus,
in analogy with the results obtained in the gut, the crosstalk between the host and fungi might be
regulated by PLP levels dictated by the microbiome that, in turn, influence the flux of Trp in the host
and microbes. Of note, 3-IAld administration protected from infection and inflammation in a mouse
model of aspergillosis (manuscript submitted), supporting the notion that correcting the Trp flux might
provide beneficial effects.
Other examples of microbiome influence on Trp metabolic pathways dependent on vitamin B6
may be hypothesized. For instance, vitamin B6 levels may modulate the production of serotonin
by enterochromaffin cells. It has been reported that the gut microbiome stimulates the synthesis of
serotonin by producing metabolites that directly stimulate colonic ECs to produce serotonin [116].
In addition to the proposed mechanism, the requirement for the microbiome might also be linked to
the production of vitamin B6 that is required for the PLP-dependent activity of AADC that converts
5-hydroxytryptophan to serotonin. It is interesting to note that, while vitamin B6 may modulate Trp
metabolism by influencing the activity of PLP-dependent enzymes, Trp metabolites can influence
vitamin B6 metabolism as well [117].
In conclusion, vitamin B6 and Trp synthesis and metabolism in the gut and other tissues may
crosstalk by intersecting multiple host and microbial pathways with potential implications in the
regulation of the mucosal immune response and the synthesis of bioactive molecules.
5. Vitamin B6 Dysregulation in Diseases of the Gastrointestinal Tract
Since vitamin B6 may regulate crucial physiological events associated with Trp metabolism
in the host and the microbes, the possibility exists that a dysregulation in the levels of vitamin B6
results in pathological conditions. An elegant perspective on the role of Trp metabolism in the
crosstalk between the host and the microbiome in health and disease has been recently reviewed [4].
The authors discuss how a disequilibrium between the serotonin, Kyn-IDO, and indole-AhR pathways
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might be causative of pathological conditions and that re-establishing the correct Trp flux could
represent a therapeutic approach. For instance, on the one hand, Crohn’s disease (CD) and ulcerative
colitis (UC) are characterized by a reduced AhR pathway, and AhR agonists or AhR-activating
probiotics might be beneficial. On the other hand, irritable bowel syndrome (IBS) with constipation
and IBS with diarrhea are characterized by a reduced or increased Tph1 pathway, respectively, and,
accordingly, 5-HT4 receptor agonists or 5-HT3 receptor antagonists are suggested as therapy [4].
We can hypothesize that re-establishing vitamin B6 homeostasis might re-equilibrate the flux along
the different metabolic pathways by restoring the proper functional activities of the PLP-dependent
enzymes that populate each pathway. For instance, patients with active CD and UC have significantly
lower plasma PLP concentrations than patients with quiescent disease or healthy controls [118] and an
inverse relationship has been shown between vitamin B6 intake and the severity of IBS symptoms [119].
Similarly, patients with celiac disease are reported as vitamin B6-deficient [120,121]. This would
suggest that dietary supplementation with vitamin B6 might be therapeutic. However, this clinical
transition might not be straightforward. For instance, study in animal models of inflammatory bowel
disease have provided unpredictable results [122]. Indeed, B6 deficiency was initially shown to be
protective in DSS-induced colitis [123] while a subsequent study reported a bell-shaped response curve
in which moderate vitamin B6 supplementation and mild depletion significantly reduced colonic
inflammation [124]. This variability might be related to the wide variety of enzymatic reactions to
which PLP participates, as well as to the different repartitioning of the Trp flux in different organs
and tissues. For instance, the Trp flux, as determined by Trp availability, quality, and quantity of
PLP-dependent enzymes, and composition and metabolic profile of the microbiome, might be different
such that modulating the vitamin B6 levels systemically might impact the Trp flux at distinct sites with
opposite outcomes. A vitamin B6-based approach requires a local characterization of PLP-dependent
reactions and a proper calibration, either by modulating the microbiome or selected host enzymatic
activities, in order to redirect the flux of Trp where it is needed and optimize the efficacy/safety profile.
6. Vitamin B6 Dysregulation in Immunology
The immune system is highly dependent on vitamin availability for the control and prevention of
infections as opportunistic infections or in general to control immune escape in terms of cancer cells.
In particular, vitamin B6 deficiency is very common in the field of malnutrition and it is known that it
may severely impact the fitness of the host immune system [125]. In general, vitamin B6 deficiency has
been associated with different diseases, leading to autoinflammation as well as cancer development.
First studies supported the idea that B6 deficiency would lead to immunocompromision as for the
impact on T cell polarization or antibody production [126].
In addition, several studies highlight that vitamin B6 deficiency and consequently PLP low plasma
levels inversely correlate with inflammatory markers as protein C reactive, but highly predispose to
systemic inflammation as coronary artery disease, atherosclerosis, and rheumatoid arthritis [127,128].
More recently, mechanistically speaking, vitamin B6 has been demonstrated to reduce IL-1β
release by macrophages. These results may also explain how vitamin B6 deficiency may chronically
activate NALP3 inflammasome and predispose an individual to inflammatory diseases [129].
Interestingly, in patients with rheumatoid arthritis, a therapy supported by vitamin B6
supplementation (100 mg/day) reduces plasma IL-6 and TNF-α cytokine production.
However, the anti-inflammatory mechanisms of vitamin B6 are not totally clarified in the
immunological fields. A novel hypothesis may relate vitamin B6 and Trp catabolism to inflammatory
status [130], knowing that two major Trp catabolic enzymes, IDO or Tph1, are especially known to
regulate peripheral tolerance in infections or autoimmune diseases [131].
In the GI tract, serotonin is synthesized by specialized endocrine cells, called enterochromaffin
cells, as well as mucosal mast cells [132] and myenteric neurons [133]. Tph1 was also found to be
expressed in Th0, Th1, Th2, and iTreg-polarized cells [131]. Interestingly, Tph1 activation by NAD+
was found to protect against multiple sclerosis, an autoimmune disease where autoreactive T cells
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progressively react against self-antigens [131]. In this study, authors found that Tph1 was able to
regulate T cell polarization and ameliorate autoimmune disease in mice. This may underline the
importance of vitamin B6 in T cell polarization and peripheral control of inflammation [131].
To further confirm this consideration, clinical studies also proved that vitamin B6 may also regulate
myelination and remyelination in multiple sclerosis patients [134].
Thus, few studies were focused on the role of vitamin B6 on peripheral tolerance, which might
be very important since both Tph1 and IDO were demonstrated to be players of tolerogenic immune
responses. Indeed, in opportunistic diseases, where tolerance is “protective” for immune functions [135],
vitamin B6 may definitively regulate the whole process.
7. Conclusions
The complex network of host and microbial metabolic pathways centered around Trp outlines
the importance of Trp metabolites in different physiological processes. The comprehension of the
relationships that keep the whole network together opens up great opportunities for therapeutic
interventions, but solving the puzzle is a challenging task. In the present opinion, we provided an
interpretative key to this network by highlighting the critical role played by PLP-dependent enzymes
in Trp metabolism. The description of each enzyme along with its dependence on PLP could represent
a starting point for the elaboration of an algorithm that takes into account the local concentration of
vitamin B6 and the specific host and microbial PLP enzymes to predict the direction of Trp flux and
the relative proportion of Trp metabolites that will be generated. Although much work is needed
to delineate the Trp metabolic network under this perspective, we believe that placing emphasis on
vitamin B6 might direct future work on Trp metabolism in health and disease.
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